Answers are grounded in this paper and cite their sources.
Randomized trial evaluates sticker reminders that increase IV-to-PO conversion in hospitalized patients, suggesting effective intervention.
To evaluate the effectiveness of a simple sticker reminder in increasing intravenous-to-oral (IV-to-PO) fluoroquinolone (FQ) conversion rates. Single-center, cluster-randomized controlled trial. Forty-five general wards at Siriraj Hospital, Bangkok, Thailand, from July 2020 through December 2024. Hospitalized adult patients receiving intravenous fluoroquinolones who met predefined IV-to-PO conversion criteria. Wards were randomized 1:1 to either a sticker reminder intervention or standard care. In the intervention group, a reminder sticker was placed on the vital signs sheet of eligible patients. The primary outcome was the proportion of IV-to-PO conversion in the intention-to-treat (ITT) and modified intention-to-treat (mITT) populations. A total of 168 patients were enrolled (85 intervention, 83 control). In the ITT population, the IV-to-PO conversion rate was 58.8% in the intervention group versus 42.2% in the control group ( p-value = 0.03). In the mITT population (patients meeting all conversion criteria), the intervention group had a significantly higher conversion rate (69.0% vs. 48.5%; p-value = 0.01). No significant differences were observed in clinical cure rates, in-hospital mortality, length of stay, duration of either IV FQ or PO FQ therapy. A sticker reminder intervention effectively increases IV-to-PO FQ conversion among eligible patients without compromising clinical safety. Future large-scale and qualitative studies are needed to further validate these benefits and explore prescriber hesitation. ClinicalTrials.gov NCT07361185 (retrospectively registered on 22 January 2026).
No takes yet. Share an insight, caveat, or question.
Sakchainan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: